4.87MMarket Cap-0.15P/E (TTM)
1.5999High1.5400Low47.53KVolume1.5700Open1.5400Pre Close74.73KTurnover1.58%Turnover RatioLossP/E (Static)3.07MShares18.719252wk High1.21P/B4.78MFloat Cap1.410052wk Low--Dividend TTM3.01MShs Float329609.2800Historical High--Div YieldTTM3.89%Amplitude1.4100Historical Low1.5720Avg Price1Lot Size
Sonnet BioTherapeutic Stock Forum
Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology
Tuesday, 28th January at 9:05 am
European Patent Office (EPO) grants EU Patent No. EP3583125 B1 covering the Company's Fully Human Albumin Binding (FHAB®) domain fusion proteins
In addition to the U.S. and EU, Sonnet's global IP coverage
now extends to China, Japan, Russia and New Zealand
Management releases "What This Mea...
Benzinga· just
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas
Tuesday, 21st January at 9:05 am
SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination evaluation with trabectedin (Yondelis®) with the potential to improve trabectedin's therapeutic window in soft-tissue sarcoma patients
Combined mechan...
📊⚡️📊
any chance of rise short term?
Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
PRINCETON, NJ, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet") (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it has entered into a definitive agreement with institutional investors for the purchase and sal...
📊⚡️📊
📊⚡️📊
No comment yet